Updates are available Correction dated 2019-04-12
Click to view Correction: https://doi.org/10.1038/s42255-019-0064-5
-
Authors
Rauner, Martina http://orcid.org/0000-0002-4067-6799
Baschant, Ulrike
Roetto, Antonella
Pellegrino, Rosa Maria
Rother, Sandra
Salbach-Hirsch, Juliane http://orcid.org/0000-0001-7097-9953
Weidner, Heike
Hintze, Vera http://orcid.org/0000-0002-5611-9903
Campbell, Graeme
Petzold, Andreas
Lemaitre, Regis
Henry, Ian
Bellido, Teresita
Theurl, Igor
Altamura, Sandro
Colucci, Silvia
Muckenthaler, Martina U.
Schett, Georg
Komla-Ebri, Davide S. K.
Bassett, J. H. Duncan http://orcid.org/0000-0003-0817-0082
Williams, Graham R. http://orcid.org/0000-0002-8555-8219
Platzbecker, Uwe
Hofbauer, Lorenz C.
- License Information
-
More Information
Article History
Received: 20 July 2018
Accepted: 19 October 2018
First Online: 7 January 2019
Change Date: 12 April 2019
Change Type: Correction
Change Details: In the version of this article initially published, affiliation 14 was incorrect, and Deutsche Forschungsgemeinschaft grants SFB1036 and SFB1118 were missing from the Acknowledgements. The errors have been corrected in the HTML and PDF versions of the article.
Competing interests
: The Technische Universität Dresden holds a patent for the use of Tfr2-ECD to treat heterotopic ossification and other related bone excess diseases (PCT/EP2018/065846). Moreover, a patent application has been filed at the European Patent Office for the use of Tfr2 blockade for the treatment of bone and haematological diseases (#18 177 441.5, 19.06.2018). M.R., U.B., U.P., and L.C.H. are the inventors of both patents. I.T. is a consultant for Kymab Ltd. The other authors declare no competing interests.
